OncoCyte Capital Stock from 2010 to 2024

OCX Stock

USD 2.44 0.09 3.56%

OncoCyte Corp Capital Stock yearly trend continues to be fairly stable with very little volatility. Capital Stock will likely drop to about 222.7 M in 2024. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals

Capital Stock

First Reported

2010-12-31

Previous Quarter

310.3 M

Current Value

222.7 M

Quarterly Volatility

89.1 M

Credit Downgrade

Yuan Drop

Covid

Check OncoCyte Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OncoCyte Corp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 49.4 K or Selling General Administrative of 11.2 M, as well as many indicators such as Price To Sales Ratio of 12.09, Dividend Yield of 0.0015 or PTB Ratio of 0.71. OncoCyte financial statements analysis is a perfect complement when working with OncoCyte Corp Valuation or Volatility modules.

Check out the analysis of OncoCyte Corp Correlation against competitors.

For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.

Latest OncoCyte Corp's Capital Stock Growth Pattern

Below is the plot of the Capital Stock of OncoCyte Corp over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. OncoCyte Corp's Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OncoCyte Corp's overall financial position and show how it may be relating to other accounts over time.

Capital Stock

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Capital Stock

Timeline

OncoCyte Capital Stock Regression Statistics

	Arithmetic Mean	135,685,814
	Geometric Mean	114,219,683
	Coefficient Of Variation	65.68
	Mean Deviation	74,612,953
	Median	74,742,000
	Standard Deviation	89,114,595
	Sample Variance	7941.4T
	Range	235.6M
	R-Value	0.83
	Mean Square Error	2714.7T
	R-Squared	0.68
	Significance	0.0001
	Slope	16,463,073
	Total Sum of Squares	111179.8T

OncoCyte Capital Stock History

	2024	222.7 M
	2023	310.3 M
	2022	294.9 M
	2021	253 M
	2020	157.2 M
	2019	124.6 M

Other Fundumenentals of OncoCyte Corp

Issuance Of Capital Stock

OncoCyte Corp Capital Stock component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Short Long Term Debt	Current Deferred Revenue	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments	Net Receivables
Total Assets		0.95	-0.8	-0.75	0.98	-0.55	0.98	0.88	-0.04	0.93	0.8	0.82	-0.71	0.72	0.65	0.55	0.68	0.92	0.73	0.86	-0.78	0.82
Total Stockholder Equity	0.95		-0.82	-0.68	0.91	-0.59	0.88	0.91	-0.1	0.84	0.74	0.79	-0.5	0.79	0.72	0.59	0.75	0.98	0.76	0.76	-0.63	0.69
Net Debt	-0.8	-0.82		0.54	-0.85	0.62	-0.74	-0.96	0.44	-0.74	-0.6	-0.56	0.4	-0.6	-0.41	-0.62	-0.6	-0.75	-0.85	-0.58	0.61	-0.68
Retained Earnings	-0.75	-0.68	0.54		-0.76	0.76	-0.76	-0.58	0.26	-0.88	-0.99	-0.97	0.58	-0.73	-0.7	-0.73	-0.75	-0.67	-0.3	-0.96	0.89	-0.64
Accounts Payable	0.98	0.91	-0.85	-0.76		-0.56	0.98	0.9	-0.14	0.93	0.8	0.8	-0.73	0.68	0.57	0.57	0.64	0.86	0.73	0.86	-0.83	0.85
Short Term Investments	-0.55	-0.59	0.62	0.76	-0.56		-0.5	-0.56	0.47	-0.61	-0.77	-0.72	0.14	-0.75	-0.77	-0.93	-0.82	-0.57	-0.29	-0.64	0.52	-0.37
Total Liab	0.98	0.88	-0.74	-0.76	0.98	-0.5		0.82	0.0	0.94	0.79	0.8	-0.82	0.64	0.57	0.5	0.61	0.84	0.67	0.87	-0.84	0.87
Total Current Assets	0.88	0.91	-0.96	-0.58	0.9	-0.56	0.82		-0.24	0.8	0.65	0.64	-0.48	0.65	0.47	0.57	0.63	0.88	0.9	0.65	-0.65	0.76
Short Term Debt	-0.04	-0.1	0.44	0.26	-0.14	0.47	0.0	-0.24		-0.1	-0.24	-0.16	-0.18	-0.2	-0.15	-0.53	-0.25	0.03	-0.03	-0.14	0.17	-0.05
Intangible Assets	0.93	0.84	-0.74	-0.88	0.93	-0.61	0.94	0.8	-0.1		0.91	0.9	-0.8	0.64	0.57	0.6	0.64	0.83	0.6	0.92	-0.93	0.79
Common Stock	0.8	0.74	-0.6	-0.99	0.8	-0.77	0.79	0.65	-0.24	0.91		0.99	-0.6	0.75	0.72	0.74	0.77	0.74	0.37	0.96	-0.89	0.66
Property Plant Equipment	0.82	0.79	-0.56	-0.97	0.8	-0.72	0.8	0.64	-0.16	0.9	0.99		-0.59	0.77	0.77	0.7	0.78	0.79	0.36	0.95	-0.85	0.62
Net Tangible Assets	-0.71	-0.5	0.4	0.58	-0.73	0.14	-0.82	-0.48	-0.18	-0.8	-0.6	-0.59		-0.18	-0.18	-0.17	-0.18	-0.51	-0.34	-0.67	0.82	-0.7
Long Term Debt	0.72	0.79	-0.6	-0.73	0.68	-0.75	0.64	0.65	-0.2	0.64	0.75	0.77	-0.18		0.84	0.72	0.98	0.76	0.55	0.75	-0.51	0.48
Short Long Term Debt	0.65	0.72	-0.41	-0.7	0.57	-0.77	0.57	0.47	-0.15	0.57	0.72	0.77	-0.18	0.84		0.77	0.83	0.71	0.22	0.68	-0.37	0.37
Current Deferred Revenue	0.55	0.59	-0.62	-0.73	0.57	-0.93	0.5	0.57	-0.53	0.6	0.74	0.7	-0.17	0.72	0.77		0.78	0.57	0.29	0.61	-0.5	0.36
Long Term Debt Total	0.68	0.75	-0.6	-0.75	0.64	-0.82	0.61	0.63	-0.25	0.64	0.77	0.78	-0.18	0.98	0.83	0.78		0.74	0.5	0.73	-0.53	0.44
Net Invested Capital	0.92	0.98	-0.75	-0.67	0.86	-0.57	0.84	0.88	0.03	0.83	0.74	0.79	-0.51	0.76	0.71	0.57	0.74		0.74	0.73	-0.62	0.66
Net Working Capital	0.73	0.76	-0.85	-0.3	0.73	-0.29	0.67	0.9	-0.03	0.6	0.37	0.36	-0.34	0.55	0.22	0.29	0.5	0.74		0.42	-0.45	0.64
Capital Stock	0.86	0.76	-0.58	-0.96	0.86	-0.64	0.87	0.65	-0.14	0.92	0.96	0.95	-0.67	0.75	0.68	0.61	0.73	0.73	0.42		-0.91	0.75
Long Term Investments	-0.78	-0.63	0.61	0.89	-0.83	0.52	-0.84	-0.65	0.17	-0.93	-0.89	-0.85	0.82	-0.51	-0.37	-0.5	-0.53	-0.62	-0.45	-0.91		-0.75
Net Receivables	0.82	0.69	-0.68	-0.64	0.85	-0.37	0.87	0.76	-0.05	0.79	0.66	0.62	-0.7	0.48	0.37	0.36	0.44	0.66	0.64	0.75	-0.75

Click cells to compare fundamentals

About OncoCyte Corp Financial Statements

OncoCyte Corp investors use historical fundamental indicators, such as OncoCyte Corp's Capital Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in OncoCyte Corp. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Capital Stock	310.3 M	222.7 M
Issuance Of Capital Stock	13.8 M	13.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for OncoCyte Stock Analysis

When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

OncoCyte Capital Stock from 2010 to 2024

Latest OncoCyte Corp's Capital Stock Growth Pattern

OncoCyte Capital Stock Regression Statistics

OncoCyte Capital Stock History

Other Fundumenentals of OncoCyte Corp

OncoCyte Corp Capital Stock component correlations

About OncoCyte Corp Financial Statements

Also Currently Popular

Additional Tools for OncoCyte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY